KYTHERA BIOPHARMACEUTICALS INC 4
4 · KYTHERA BIOPHARMACEUTICALS INC · Filed Nov 5, 2013
Insider Transaction Report
Form 4
Webster Jeffrey D
Senior VP, Operations
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2013-11-01−1,900→ 62,761 totalExercise: $0.76Exp: 2017-03-13→ Common Stock (1,900 underlying) - Exercise/Conversion
Stock Option (right to buy)
2013-11-01−2,100→ 64,661 totalExercise: $0.76Exp: 2017-03-13→ Common Stock (2,100 underlying) - Sale
Common Stock
2013-11-01$44.56/sh−2,100$93,569→ 0 total - Exercise/Conversion
Common Stock
2013-11-01$0.76/sh+2,100$1,596→ 2,100 total - Exercise/Conversion
Common Stock
2013-11-01$0.76/sh+1,900$1,444→ 1,900 total - Sale
Common Stock
2013-11-01$45.29/sh−1,900$86,046→ 0 total
Footnotes (4)
- [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan which expires April 30, 2014.
- [F2]100% of the shares subject to the option are fully vested and exercisable.
- [F3]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $44.15 to $45.00, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $45.015 to $45.5633, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.